Lexaria keeps Nasdaq listing after bid-price fix

Lexaria Bioscience Corp. reported that on August 17, 2026 it received notice from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Lexaria Bioscience Corp. reported that on August 17, 2026 it received notice from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, the previously requested Nasdaq hearing has been cancelled, and the company’s common stock will continue to be listed and trade on The Nasdaq Capital Market. This removes an overhang related to potential delisting and clarifies that the company currently meets Nasdaq’s bid price standards.

Positive

• Nasdaq confirmed Lexaria regained compliance with the bid price requirement under Rule 5550(a)(2), removing an immediate delisting risk.
• The previously requested Nasdaq hearing was cancelled, and the company’s common stock will continue trading on The Nasdaq Capital Market.

Negative

• None.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Compliance confirmation date: August 17, 2026 Listing rule: Nasdaq Listing Rule 5550(a)(2) Trading symbol: LEXX

3 metrics

Compliance confirmation date August 17, 2026 Date Nasdaq confirmed Lexaria had regained compliance with the bid price requirement

Listing rule Nasdaq Listing Rule 5550(a)(2) Bid price requirement Lexaria is now in compliance with

Trading symbol LEXX Common stock symbol listed on The Nasdaq Capital Market

Key Terms

Nasdaq Listing Rule 5550(a)(2), bid price requirement, The Nasdaq Capital Market, Emerging growth company

4 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2)"

bid price requirement market

"regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2)"

A bid price requirement is a rule that specifies the minimum price a buyer must offer per share when making an official purchase proposal, tender offer, auction bid, or similar transaction. It matters to investors because it sets a floor for negotiations and valuation—like a reserve price in an auction—ensuring bids meet regulatory, contract or market standards and helping shareholders and markets judge whether an offer is fair or likely to succeed.

The Nasdaq Capital Market market

"the Company’s Common Stock will continue to be listed and trading on The Nasdaq Capital Market"

A tier of the Nasdaq stock exchange that hosts smaller or early-stage public companies that meet defined listing standards for size, share price and governance. Think of it as a particular shelf in a store for emerging brands: it gives investors a centralized place to find and trade these stocks while signaling that the companies meet basic regulatory and financial rules. Investors watch it for growth opportunities and higher volatility compared with larger markets.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexaria Bioscience Corp. (LEXX) announce regarding its Nasdaq listing status?

Lexaria announced that Nasdaq confirmed it has regained compliance with the minimum bid price requirement, so its common stock will continue to be listed and trading on The Nasdaq Capital Market and the previously requested hearing has been cancelled.

Which Nasdaq rule did Lexaria (LEXX) regain compliance with?

Lexaria regained compliance with the Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid price requirement for continued listing on The Nasdaq Capital Market, according to the notice received from the Nasdaq Hearings Advisor.

What happened to the previously requested Nasdaq hearing for Lexaria (LEXX)?

The previously requested Nasdaq hearing has been cancelled because Nasdaq Listings Qualifications Staff confirmed Lexaria had regained compliance with the bid price requirement, removing the immediate need for a listing-hearings process.

Will Lexaria Bioscience Corp. (LEXX) remain listed on The Nasdaq Capital Market?

Yes. The company stated that its common stock will continue to be listed and trading on The Nasdaq Capital Market after Nasdaq confirmed Lexaria’s compliance with the bid price requirement in Rule 5550(a)(2).

When did Lexaria (LEXX) receive confirmation of regained Nasdaq bid price compliance?

Lexaria received confirmation on August 17, 2026, via a letter from the Nasdaq Hearings Advisor indicating the Nasdaq Listings Qualifications Staff had confirmed compliance with the bid price requirement under Listing Rule 5550(a)(2).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 12:38 PM Accepted by SEC EDGAR 08/17/2026 - 12:37 PM Learn about SEC filing dates

0001348362false00013483622026-08-172026-08-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  August 17, 2026

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

Nevada		000-39874		20-2000871
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 – 740 McCurdy Road, Kelowna, BC Canada		V1X 2P7
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (250) 765-6424

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		LEXX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 8.01 Other Events

Cure of Nasdaq Bid Price Deficiency

On August 17, 2026, Lexaria Bioscience Corp. (the “Company”) received a letter from the Hearings Advisor of The Nasdaq Stock Market (“Nasdaq”) advising that the Nasdaq Listings Qualifications Staff had confirmed that the Company had regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2).  Consequently, the previously requested hearing has been cancelled and the Company’s Common Stock will continue to be listed and trading on The Nasdaq Capital Market.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEXARIA BIOSCIENCE CORP.

/s/ Richard Christopher

Richard Christopher

CEO, Principal Executive Officer

Date: August 17, 2026

3

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.3 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.0 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB